Sykehuset Innlandet HF
- Address
- lock Available on a paid plan
Sykehuset Innlandet HF - Clinical Research Center
Sykehuset Innlandet HF is a comprehensive clinical research center conducting diverse therapeutic investigations across multiple medical specialties. The center demonstrates particular expertise in oncology, with significant focus on advanced lung cancer treatments combining immunotherapy, chemotherapy, and radiotherapy approaches. Their research portfolio reflects a commitment to precision medicine and innovative treatment strategies for both common and rare conditions.
- Lung Cancer: Advanced studies in non-small cell lung cancer (NSCLC) and small-cell lung cancer combining immunotherapy with radiotherapy and targeted therapies
- Precision Oncology: Implementation of genomic-guided targeted therapies for advanced malignancies and rare cancers through precision medicine initiatives
- Endocrine Disorders: Research in primary adrenal insufficiency treatment optimization and diabetic peripheral neuropathy management
- Specialized Therapeutics: Novel interventions including hyperbaric oxygen therapy for sudden sensorineural hearing loss and thrombolytic therapy for central retinal artery occlusion
The center's research extends to gastrointestinal immunology with studies on celiac disease symptom management, advanced prostate cancer with DNA damage repair gene mutations, and surgical innovations including tranexamic acid use in plastic surgery. This multidisciplinary approach positions Sykehuset Innlandet HF as a leader in both common disease management and rare condition research, with emphasis on translating precision medicine concepts into clinical practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Region Skane1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sykehuset Innlandet HF
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) | Oslo University Hospital HF | Phase II | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 1 | Unknown | 2020-08-18 | 2020-08-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.